Enamine, a chemical research organisation and TBD Biodiscovery, a GMP manufacturer of fine chemicals have announced a collaboration agreement to manage the transition of chemical synthesis of novel intermediates from laboratory to bulk scale under GMP standards.
This will help researchers meet the manufacturing feasibility criteria required for drug candidate selection, providing a rapid and cost-effective scaled supply of new compounds.
Dr Vladimir Ivanov, Chief of sales and marketing at Enamine, commented: ‘We recognise that the building blocks we synthesise are being incorporated into the development of new drugs. We are confident that by working in partnership with TBD Biodiscovery with their extensive experience in providing synthesis services under GMP, we can further extend the support we provide and help streamline the manufacturing process.’
Enamine’s catalogue of building blocks is the largest in the world and has been widely used by pharmaceutical companies for more than 15 years to develop lead compounds and drug candidates. With syntheses of these compounds first realised by Enamine, the company holds specialist knowledge that can be critical to successful scale-up. In the announced collaboration Enamine will optimise synthesis processes while TBD Biodiscovery will use the developed protocols to manufacture requested products to GMP standard.
Dr Andrus Tasa, chairman of the Management Board of TBD Biodiscovery, adds: ‘I have been very impressed by the creativity of Enamine’s chemists in designing new chemical synthesis. We are happy to have Enamine’s support in optimising the chemical processes used by us for GMP manufacture.’
